Patient Characteristics
| Characteristic | Data |
|---|---|
| Age (y) | 73 (range, 52–92) |
| ECOG performance status 0 or 1 | 96 (96%) |
| Site of disease | |
| Lung | 15 (15%) |
| Liver | 22 (22%) |
| Lymph node | 71 (71%) |
| Bone | 95 (95%) |
| PSA level (ng/mL) | 18.6 (range, 0.1–1,728.032) |
| Gleason score at diagnosis | |
| 8–10 | 58 (58%) |
| Unknown | 19 (19%) |
| Previous prostatectomy | 31 (31%) |
| Previous androgen-receptor-pathway inhibitor | |
| One regimen | 30 (30%) |
| Two regimens | 66 (66%) |
| More than 2 regimens | 3 (3%) |
| Previous taxane therapy | |
| One regimen | 65 (65%) |
| Two regimens | 34 (34%) |
| PSMA SUVmax at baseline | 35.3 (interquartile range, 25.0–60.8) |
ECOG = Eastern Cooperative Oncology Group.
Qualitative data are number and percentage; continuous data are median.